Changeflow GovPing Healthcare & Life Sciences Phase 3 Neuroblastoma Trial With hu14 Antibody
Routine Notice Added Final

Phase 3 Neuroblastoma Trial With hu14 Antibody

Email

Summary

A Phase 3 clinical trial evaluating hu14 antibody for neuroblastoma has been registered on ClinicalTrials.gov. The trial is listed as recruiting participants and includes standard registry information on study design and eligibility criteria. This entry provides public visibility into ongoing late-stage oncology research.

Published by NIH on clinicaltrials.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors ClinicalTrials.gov - Phase 3 Trials by Start Date for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 12 changes logged to date.

What changed

A new Phase 3 clinical trial for neuroblastoma using the hu14 antibody has been registered on ClinicalTrials.gov. The registry entry contains standard trial metadata including NCT number NCT07549321, phase classification, and recruitment status.

Affected parties include clinical investigators, oncology research institutions, and patients seeking late-stage clinical trial options. The entry serves an informational and transparency function rather than creating compliance obligations.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Show glossary

Get daily alerts for ClinicalTrials.gov - Phase 3 Trials by Start Date

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Clinical investigators Healthcare providers
Industry sector
6211 Healthcare Providers
Activity scope
Clinical trial registration Oncology research
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when ClinicalTrials.gov - Phase 3 Trials by Start Date publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!